Redeye provides an initial comment on the Q4 2024 report from Catella.
Taaleri’s group continuing earnings grew 6% y/y to EUR 10.
Sprint Bioscience delivered Q4 sales within the recent range at SEK 16.
Q4 EBIT of SEK 63m, +19% vs. ABGSC and +13% vs. cons.
Redeye comments on Vertiseit’s Q4 report, with ARR and EBITDA-CAPEX roughly matching our expectation...
Nettoomsättningen för det tredje kvartalet uppgick till 119,6 MSEK (99,8), vilket motsvarade en orga...
Redeye retains its positive view of Sdiptech following a stable Q4 report.
Redeye retains its view of Hanza following a Q4 report showing a relatively solid performance in a s...
Q4e: organic growth acceleration to 20%, stable margin Small adj.
Beat on adj. EBIT but lower OCF Adj. EBIT up 8.9-9.
Q4 better than expected, adj. EBITA +0-2% Financial flexibility for divi, buybacks & M&A with curren...
Analyst Group inleder idag den 11:e februari 2024 analysbevakning på Hifab Group (”Hifab”, ”Koncerne...
Redeye offers a preview of Binero's H2-24 results set to be released on February 21.
Tough end to 2024 Market to turn positive in '25e, according to report Re-setting expectation, '25e ...
CapMan reports Q4 results on February 13th. Fundraising activities are of more interest, with financ...
Tessin tillhandahåller en digital investeringsplattform för säkerställda fastighetslån.
Redeye believes Sdiptech's Q4 report was solid, with negative organic sales growth but higher margin...
Adj. EBIT +85% vs ABGSCe Soft cash flow generation Estimates likely up 10% on adj.
Hyresintäkterna steg till 3 438 (3 366) mkr, varav 861 (827) mkr i det fjärde kvartalet.
Net sales SEK 537m, +3% vs ABGSCe, 0% vs Factset cons.
